Nasdaq ikna.

Ikena Oncology, Inc. (IKNA) NasdaqGM - NasdaqGM Real Time Price. Currency in USD. Follow. 2W 10W 9M. 1.6700 +0.0900 (+5.70%) As of 10:38AM EST. Market open. 1d. Nov 10, 2022 · BOSTON, Nov. 10, 2022 (GLOBE NEWSWIRE) -- Ikena Oncology, Inc. (Nasdaq: IKNA, “Ikena”), a targeted oncology company forging new territory in patient-directed cancer treatment, today presented ... Jun 28, 2021 · Every investor in Ikena Oncology, Inc. (NASDAQ:IKNA) should be aware of the most powerful shareholder groups. Insiders often own a large chunk of younger, smaller, companies while huge companies ... Ikena Oncology (NASDAQ:IKNA) and Sangamo Therapeutics (NASDAQ:SGMO) are both small-cap medical companies, but which is the superior investment?We will contrast the two companies based on the strength of their media sentiment, analyst recommendations, dividends, community ranking, earnings, profitability, valuation, institutional ownership and risk.Source: Kantar Media. View the latest Ikena Oncology Inc. (IKNA) stock price, news, historical charts, analyst ratings and financial information from WSJ.

BOSTON, Oct. 05, 2022 (GLOBE NEWSWIRE) -- Ikena Oncology, Inc. (Nasdaq: IKNA, “Ikena”), a targeted oncology company forging new territory in patient-directed cancer treatment, today announced ...

(NASDAQ: IKNA) Ikena Oncology currently has 48,258,111 outstanding shares. With Ikena Oncology stock trading at $1.40 per share, the total value of Ikena Oncology stock (market capitalization) is $67.56M.Ikena Oncology. stock was originally listed at a price of $28.30 in Mar 29, 2021.

BOSTON, Nov. 07, 2023 (GLOBE NEWSWIRE) -- Ikena Oncology, Inc. (Nasdaq: IKNA, “Ikena,” “Company”), a targeted oncology company forging new territory in patient-directed cancer treatment, today announced that management will participate in three upcoming investor conferences in November.. Details are as follows: Stifel Healthcare Conference, …BOSTON, Sept. 05, 2023 (GLOBE NEWSWIRE) -- Ikena Oncology, Inc. (Nasdaq: IKNA, “Ikena,” “Company”), a targeted oncology company forging new territory in patient-directed cancer treatment ...17 avr. 2023 ... BOSTON, April 17, 2023 (GLOBE NEWSWIRE) -- Ikena Oncology, Inc. (Nasdaq: IKNA ... NASDAQ:IKNA. IKNA Rankings. #5626 Ranked by Market Cap. #614 ...Nasdaq Fund Secondaries; Featured Solutions Nasdaq's IPO Process; ETF Listings; Nasdaq-100 Index Options; Derivatives AcademyTo learn more about the company, technology solutions and career opportunities, visit us on LinkedIn, on Twitter @Nasdaq, or at www.nasdaq.com. Media Contact Emily Pan [email protected] +1 (646 ...

IKNA Price $1.40 Fair Value Price N/A Market Cap $67.56M 52 Week Low $1.02 52 Week High $7.64 P/E -0.86x P/B 0.43x P/S 13.48x PEG N/A Dividend Yield N/A …

Selected Balance Sheet Items: September 30, 2023 December 31, 2022: Cash and cash equivalents $ 121,277 $ 59,919 Marketable securities $ 75,656

Ikena Oncology (NASDAQ:IKNA shareholders incur further losses as stock declines 16% this week, taking one-year losses to 79%. (Simply Wall St.) Mar-17-22 07:00AM. Ikena Oncology Reports Fourth Quarter and Full Year 2021 Financial Results and Corporate Update. (GlobeNewswire) +23.30%.Here’s What You Need To Know. By JESSICA GRANT. Sep 21, 2022. As the world’s largest furniture retailer for nearly 15 years, investors want to own shares of IKEA stock. Table of Contents show. The Swedish furniture company is known worldwide for its do-it-yourself furniture, meatballs, and iconic stores. The company’s growth, popularity ...Ikena Oncology Inc (NASDAQ: IKNA) is garnering attention with its oncology-focused pipeline, and the company's recent developments have raised optimism in the medical community.Gainers DiamondHead Holdings Corp. (NASDAQ: DHHC) shares jumped 104.2% to $21.15. DiamondHead entered into convertible note purchase agreement dated March 21, 2023.7 août 2023 ... (Nasdaq: IKNA, Ikena), a targeted oncology company forging new territory in patient-directed cancer treatment, and Pionyr Immunotherapeutics ...

The latest price target for . Ikena Oncology (NASDAQ: IKNA) was reported by HC Wainwright & Co. on Thursday, November 9, 2023.The analyst firm set a price target for 11.00 expecting IKNA to rise ...Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP) announced an agreement to acquire an approximately 48,000-square-foot R&D facility in Frederick, Maryland to support its expanding infectious ...BOSTON, June 22, 2022 (GLOBE NEWSWIRE) -- Ikena Oncology, Inc. (Nasdaq: IKNA, “Ikena”), a targeted oncology company forging new territory in patient-directed cancer treatment, today announced ...The stock of Ikena Oncology Inc (NASDAQ: IKNA) has increased by 20.81 when compared to last closing price of 1.49.Despite this, the company has seen a gain of 23.29% in its stock price over the last five trading days. Zacks Investment Research reported 2023-06-20 that Ikena Oncology, Inc. (IKNA) could be a great choice for investors looking to ...BOSTON, Nov. 07, 2023 (GLOBE NEWSWIRE) -- Ikena Oncology, Inc. (Nasdaq: IKNA, “Ikena,” “Company”), a targeted oncology company forging new territory in patient-directed cancer treatment, today announced that management will participate in three upcoming investor conferences in November.. Details are as follows: Stifel Healthcare Conference, …Nov. 07, 2023 (GLOBE NEWSWIRE) -- Ikena Oncology, Inc. (Nasdaq: IKNA, “Ikena,” “Company”), a targeted oncology company forging new territory in patient-directed cancer treatment, today ...The stock of Ikena Oncology Inc (NASDAQ: IKNA) has decreased by -8.11 when compared to last closing price of 1.48.Despite this, the company has seen a loss of -66.99% in its stock price over the last five trading days. Zacks Investment Research reported 2023-06-20 that Ikena Oncology, Inc. (IKNA) could be a great choice for investors looking to ...

Prior to Seismic, she served as Chief Business Officer of Ikena Oncology (Nasdaq: IKNA), a clinical-stage biotech company, where she built and managed the business development, legal and corporate strategy functions. ... where he built the finance and accounting infrastructure in support of its transition to a Nasdaq-listed public company.Follow. BOSTON, March 07, 2023 (GLOBE NEWSWIRE) -- Ikena Oncology, Inc. (Nasdaq: IKNA, “Ikena”), a targeted oncology company forging new territory in patient-directed cancer treatment, today ...

INKA Kludeln I Acquisition Corporation Current Report Filing (8-k) Support: 888-992-3836May-16-23 08:29AM · Party Time: Brokers Just Made Major Increases To Their Ikena Oncology, Inc. (NASDAQ:IKNA) Earnings Forecasts. (Simply Wall St.) -12.00% ; 09: ...BOSTON, Nov. 07, 2023 (GLOBE NEWSWIRE) -- Ikena Oncology, Inc. (Nasdaq: IKNA, “Ikena,” “Company”), a targeted oncology company forging new territory in patient-directed cancer treatment ...Nov 10, 2021 · As of September 30, 2021, the Company had cash and cash equivalents totaling $245.9 million, which will fund operations through 2023. Net cash used in operations was $18.0 million for the third ... American International Group Inc. bought a new position in Ikena Oncology, Inc. (NASDAQ:IKNA – Free Report) during the 2nd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund bought 10,232 shares of the company’s stock, valued at approximately $67,000. Other hedge funds have also added to or […]Dec 11, 2021 · About Nasdaq Nasdaq (Nasdaq: NDAQ) is a global technology company serving the capital markets and other industries. Our diverse offering of data, analytics, software, and services enables clients ... BOSTON, Nov. 28, 2022 (GLOBE NEWSWIRE) -- Ikena Oncology, Inc. (Nasdaq: IKNA, “Ikena”), a targeted oncology company forging new territory in patient-directed cancer treatment, today announced a next-generation mitogen-activated protein kinase (MEK)-RAF complex inhibitor, IK-595, has been nominated as the company’s first development ...23 mai 2023 ... Dolar, Borsa, Altın, Eurobond, Bankalar ve Nasdaq Hakkında ... İlahiyatçı Kızlar Celal Şengör'ü "Bir Yaratan" Olduğuna İkna Etmeye Çalışıyorlar.BOSTON, Nov. 10, 2022 (GLOBE NEWSWIRE) -- Ikena Oncology, Inc. (Nasdaq: IKNA, “Ikena”), a targeted oncology company forging new territory in patient-directed cancer treatment, today presented ...

Nasdaq Short Interest Days Nasdaq Short Interest Days NEW YORK, Nov. 27, 2023 (GLOBE NEWSWIRE) -- At the end of the settlement date of November 15, 2023, short interest in 3,169 Nasdaq Global ...

The Index is designed to track the performance of a set of securities listed on The Nasdaq Stock Market ® that are classified as either biotechnology or pharmaceutical according to the Industry ...

BOSTON, Oct. 26, 2022 (GLOBE NEWSWIRE) -- Ikena Oncology, Inc. (Nasdaq: IKNA, “Ikena”), a targeted oncology company forging new territory in patient-directed cancer treatment, today announced ...Mar 7, 2023 · BOSTON, March 07, 2023 (GLOBE NEWSWIRE) -- Ikena Oncology, Inc. (Nasdaq: IKNA, “Ikena”), a targeted oncology company forging new territory in patient-directed cancer treatment, today announced ... Oct 7, 2021 · BOSTON, Oct. 07, 2021 (GLOBE NEWSWIRE) -- Ikena Oncology, Inc. (Nasdaq: IKNA, “Ikena”), a targeted oncology company navigating new territory in patient-directed cancer treatment, today ... First Quarter 2022 Financial results. Ikena had $212.4 million in cash, cash equivalents, marketable securities as of March 31, 2022, as compared to $232.2 million as of December 31, 2021. Ikena ...Nov 24, 2023 · According to 4 analysts, the average rating for IKNA stock is "Strong Buy." The 12-month stock price forecast is $16.0, which is an increase of 288.35% from the latest price. The three major U.S. stock exchanges are the New York Stock Exchange (NYSE), the NASDAQ and the American Stock Exchange (AMEX). As of 2014, the NYSE is the largest and most prestigious of the three. The NASDAQ is a virtual stock exchange.Find the latest Institutional Holdings data for Ikena Oncology, Inc. Common Stock (IKNA) at Nasdaq.com. See All Market Activity. News + Insights. CLOSEBiogen Inc. (NASDAQ:BIIB) announced negative topline results from the Phase 3 STAR study of timrepigene emparvovec, an investigational gene therapy for the potential treatment of choroideremia.Nov 20, 2023 · The stock of Ikena Oncology Inc (NASDAQ: IKNA) has increased by 20.81 when compared to last closing price of 1.49.Despite this, the company has seen a gain of 23.29% in its stock price over the last five trading days. Zacks Investment Research reported 2023-06-20 that Ikena Oncology, Inc. (IKNA) could be a great choice for investors looking to ... 19 oct. 2022 ... (Nasdaq: IKNA, “Ikena”), una compañía de oncología específica que forja un nuevo territorio en el tratamiento del cáncer dirigido por el ...

Third Quarter 2022 Financial Results. As of September 30, 2022, Ikena had $174.4 million in cash, cash equivalents, and marketable securities, and believes this will be sufficient to meet its ...Ikena Oncology, Inc. (NASDAQ:IKNA), 180 Life Sciences Corp. (NASDAQ:ATNF) and Evelo Biosciences, Inc. (NASDAQ:EVLO) are among the major biopharma movers of Monday. Ikena Oncology Gains On Fund ...Advancement across Company’s pipeline towards regulatory and data milestonesBOSTON, Aug. 11, 2022 (GLOBE NEWSWIRE) -- Ikena Oncology, Inc. (Nasdaq: IKNA, “Ikena”), a targeted oncology ...Instagram:https://instagram. military friendly mortgage lendersworkers comp carriers in californiausaa motorcycle insurance phone numberbest va loan lenders in florida Ikena Oncology Stock Price, News & Analysis (NASDAQ:IKNA) $1.50 +0.05 (+3.45%) (As of 12/1/2023 ET) Compare Share Today's Range $1.42 $1.52 50-Day …Source: Kantar Media. View the latest Ikena Oncology Inc. (IKNA) stock price, news, historical charts, analyst ratings and financial information from WSJ. one month treasury bill ratemichaelburry Ikena Oncology, Inc. (NASDAQ:IKNA) fell 12.3% to $1.43 in pre-market trading. Ikena Oncology recently reported worse-than-expected third-quarter revenue results. list of money market funds Analyst Forecast According to 4 analysts, the average rating for IKNA stock is "Strong Buy." The 12-month stock price forecast is $14.25, which is an increase of …According to the issued ratings of 4 analysts in the last year, the consensus rating for Ikena Oncology stock is Buy based on the current 4 buy ratings for IKNA. The average twelve-month price prediction for Ikena Oncology is $11.67 with a high price target of $13.00 and a low price target of $11.00. Learn more on IKNA's analyst rating history.American International Group Inc. bought a new position in Ikena Oncology, Inc. (NASDAQ:IKNA – Free Report) during the 2nd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund bought 10,232 shares of the company’s stock, valued at approximately $67,000. Other hedge funds have also added to or […]